Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye tests could speed up retinitis pigmentosa treatment trials

NCT ID NCT06323772

Knowledge-focused Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find better ways to measure how retinitis pigmentosa (a genetic eye disease that causes vision loss) progresses over time. Researchers will use advanced imaging and vision tests in 40 people with specific genetic forms of the disease. The goal is to identify reliable measurements that can be used in future clinical trials to test new treatments more effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help design better clinical trials for future treatments of retinitis pigmentosa by identifying reliable ways to measure disease progression.
What could go wrong
This is an observational study, not testing a treatment. It may not lead directly to new therapies, and the findings might not apply to all forms of retinitis pigmentosa.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

40 patients with PDE6A, PDE6B, and RHO-based retinitis pigmentosa

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: from 5 years of age * Patient with PDE6A, PDE6B, and RHO-based retinitis pigmentosa * Patient and/or legal representatives are willing and able to give written informed consent Exclusion Criteria: * severe general disease, that would make longer examinations not possible

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinitis pigmentosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital stationary night blindness autosomal dominant 1 congenital stationary night blindness autosomal dominant 2 Eye Diseases, Hereditary eye disorder hereditary disease inherited retinal dystrophy retinal degeneration retinal disorder retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinitis pigmentosa

Contacts and locations

Locations

  • Institute for Ophthalmic Research, University Tübingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.